Preparation and evaluation of verapamil hydrochloride microcapsules

American Journal of Therapeutics

Volumn 12, Issue 5, 2005, Pages 417-424

  Mukherjee, Biswajit ^a   Mahanti, Beduin ^b   Panda, Prabhudutta ^c   Mahapatra, Sushmita ^a  

^a JADAVPUR UNIVERSITY   (India)

^b Department of Pharmaceutics   (India)

^c NONE

Author keywords

Cellulose acetate; Drug release kinetics; Ethylcellulose; Microencapsulation; Verapamil

Indexed keywords

CELLULOSE ACETATE; ETHYL CELLULOSE; POLYMER; VERAPAMIL;

ARTICLE; DISSOLUTION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RELEASE; DRUG SCREENING; DRUG SYNTHESIS; IN VITRO STUDY; KINETICS; MICROCAPSULE; MICROENCAPSULATION; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; TABLET FORMULATION; TABLET HARDNESS;

ADMINISTRATION, ORAL; ANTI-ARRHYTHMIA AGENTS; CAPSULES; CELLULOSE; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; EXCIPIENTS; KINETICS; MICROSCOPY, ELECTRON, SCANNING; PARTICLE SIZE; SOLUBILITY; TABLETS; VERAPAMIL;

EID: 26844484575     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mjt.0000162014.43743.e0     Document Type: Article

References (16)

1. Davis PJ, Fagan TC, Topmiller MJ, et al. Treatment of mild hypertension with low once-daily doses of a sustained-release capsule formulation of verapamil. J Clin Pharmacol. 1995;35:52-58.
2. Fuenmayor NT, Faggine BM, Cubeddu LX. Comparative efficacy, safety and pharmacokinetics of verapamil SR vs verapamil IR in hypertensive patients. Drugs. 1992;44:1-11.
3. Franz DN. Cardiovascular drugs. In: Gennaro AR, ed. Remington: The Science and Practice of Pharmacy, 19th ed. Philadelphia: Lippincott; 1995:966.
4. Kondo A. Microcapsule processing and technology. In: Van Valkenburg JW, ed. New York: Marcel Dekker; 1979.
5. Porter SC. Controlled release film coatings based on ethykellulose. Drug Dev Ind Pharm. 1989;15:1495-1521.
6. Nokodchi A, Zakeri-Milan P, Valizadeh H, et al. Evaluation of microcapsules of ASA prepared with CAP, EC or their mixtures by non-solvent addition technique. Ars Pharmaceut. 2002;43:135-147.
7. Jalsenjak I, Nixon JR, Senjkovic R, et al. Sustained-release dosage forms of microencapsulated isoniazid. J Pharm Pharmacol. 1980;32:678.
8. Fassihi AR. Kinetics of drug release from matrices. Int J Pharm. 1987;37:119-125.
9. Wagner JG. Predictability of verapamil steady-state plasma levels from single-dose data explained. Clin Pharmacol Ther. 1984;36:1-4.
10. Deasy PB. General introduction. In: Deasy PB, ed. Microencapsulation and Related Drug Process. New York: Marcel Dekker; 1984:1-14.
11. Higuchi T. Mechanism of sustained-action medication-theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci. 1963;52:1145-1149.
12. Pritza DR, Bicrman MH, Hammcke MD. Acute toxic effects of sustained-release verapamil in chronic renal failure. Arch Intern Med. 1991;151:2081-2084.
13. Yazan Y, Bozan B. Rapid analysis of verapamil in plasma by reversed phase HPLC. Pharmazie. 1995;50:117-119.
14. Lavasanifar A, Ghalandari R, Ateai R, et al. Microencapsulation of theophylline using ethykellulose: in vitro drug release and kinetic modeling. J Microencapsul. 1997;14: 91-100.
15. Sheorey DS, Sai MS, Dorle AK. A new technique for the encapsulation of water insoluble drugs using ethyl cellulose. J Microencapsul. 1991;8:359-368.
16. Beyger JW, Nairn JG. Some factors affecting the microencapsulation of pharmaceuticals with cellulose acetate phthalate. J Pharm Sci. 1986;75:573-578.